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Severine Valmary-Degano8,9, Charles M Quick6, Christopher P Crum13 and Philippe Delvenne1
BACKGROUND: Primary adenocarcinoma of the anal canal is a rare and aggressive gastrointestinal disease with unclear
pathogenesis. Because of its rarity, no clear clinical practice guideline has been deﬁned and a targeted therapeutic armamentarium
has yet to be developed. The present article aimed at addressing this information gap by in-depth characterising the anal glandular
neoplasms at the histologic, immunologic, genomic and epidemiologic levels.
METHODS: In this multi-institutional study, we ﬁrst examined the histological features displayed by each collected tumour (n= 74)
and analysed their etiological relationship with human papillomavirus (HPV) infection. The intratumoural immune cell subsets (CD4,
CD8, Foxp3), the expression of immune checkpoints (PD-1, PD-L1), the defect in mismatch repair proteins and the mutation analysis
of multiple clinically relevant genes in the gastrointestinal cancer setting were also determined. Finally, the prognostic signiﬁcance
of each clinicopathological variable was assessed.
RESULTS: Phenotypic analysis revealed two region-speciﬁc subtypes of anal canal adenocarcinoma. The signiﬁcant differences in
the HPV status, density of tumour-inﬁltrating lymphocytes, expression of immune checkpoints and mutational proﬁle of several
targetable genes further supported the separation of these latter neoplasms into two distinct entities. Importantly, anal gland/
transitional-type cancers, which poorly respond to standard treatments, displayed less mutations in downstream effectors of the
EGFR signalling pathway (i.e., KRAS and NRAS) and demonstrated a signiﬁcantly higher expression of the immune inhibitory ligand-
receptor pair PD-1/PD-L1 compared to their counterparts arising from the colorectal mucosa.
CONCLUSIONS: Taken together, the ﬁndings reported in the present article reveal, for the ﬁrst time, that glandular neoplasms of
the anal canal arise by HPV-dependent or independent pathways. These etiological differences leads to both individual immune
proﬁles and mutational landscapes that can be targeted for therapeutic beneﬁts.
British Journal of Cancer (2018) 118:1302–1312; https://doi.org/10.1038/s41416-018-0049-2
INTRODUCTION
Extending from the anal margin (also called perianal skin) to the
anorectal ring/ﬂexure, the anal canal is the terminal part of the
gastrointestinal tract. Despite its small size (~4 cm in length),
several types of neoplams may be observed within this anatomical
structure, which reﬂects its embryologic/histologic complexity.1
Accounting for ~90% of all malignant anal lesions, squamous cell
carcinomas (SCC) arise either from the external (squamous) part of
the anal canal or from the transitional zone lined by an
“urothelium-like” epithelium.2,3 Importantly, the cellular origin
was recently shown to strongly impact the protein expression
proﬁle, the differentiation as well as the outcome of these
tumours.2 Etiologically linked to HPV infection (most notably
HPV16 genotype),2,4–6 SCC are traditionally treated by surgery
(local resection) and/or chemoradiotherapy (radiation therapy
combined with mitomycin C and 5-Fluorouracil). With the
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exception of rare HPV-negative anal SCC (~5%) that are
unresponsive to these standard treatments,2,5,6 a complete
remission is achieved in the majority (~75%) of patients.7 Beside
squamous neoplasms, a few thousands of primary anal canal
adenocarcinoma are also diagnosed each year worldwide. More
aggressive than SCC and most frequently detected in older
patients (sixth decade of life),8–11 these rare tumours still represent
a diagnostic and therapeutic challenge due to the lack of in-depth
characterisation. According to a survey conducted by Abel et al.,12
most clinicians only occasionally encounter patients with anal
adenocarcinoma. Therefore, the majority of recent descriptive
studies are clinical case reports,13–15 and there is a lack of
sufﬁcient information to generate guidelines for uniform treat-
ment recommendations.16,17 Moreover, molecular perturbations
that might serve as targets for therapy are completely unknown.
In the present study, we extensively examined a multicentre
cohort of anal canal adenocarcinoma (n= 74) in order to improve
the current controversial diagnosis/management of patients. The
histologic, immunologic and mutational proﬁles of these rare
malignant glandular lesions were, for the ﬁrst time, determined
and collected results point to new opportunities for personalised
therapeutic intervention.
MATERIALS AND METHODS
Patient selection and clinical data retrieval
A total of 74 patients treated for primary anal canal adenocarci-
noma in six different medical centres (University Hospital Center
of Liege (Belgium), Citadelle Regional Hospital (Liege, Belgium),
Jules Bordet Institute (Brussels, Belgium), University Hospital
Center of Besançon (France), University Hospital of Lausanne
(Switzerland) and University of Arkansas for Medical Sciences
(Little Rock, AR, USA)) between January 1999 and October 2016
were selected. Tissue specimens (biopsies or tumour resections)
from each patient were retrieved from pathology archives with
the approval of the ethics committees of the respective
institutions. Forty normal tissue samples (haemorrhoidectomies)
displaying the three different portions of the anal canal
(squamous zone, transitional zone and colorectal zone) were also
obtained. All cases (haematoxylin and eosin (H&E) staining) were
re-examined by senior histopathologists to conﬁrm the diagnosis.
Clinicopathological data were collected for all selected patients
diagnosed with invasive adenocarcinoma of the anal canal. Patient
gender, age at diagnosis, disease stage (according to the Union for
International Cancer Control, 8th edition, 2016), HIV status,
inﬂammatory bowel disease, treatment details [local surgery,
(neo)adjuvant therapies (radiotherapy and/or chemotherapy),
abdomino-perineal resection] and follow-up data were obtained
from patient’s medical records. Tumour differentiation was
determined using established criteria (Supplementary Figure 1).
Patients with downward spread from a rectal tumour, associated
with incomplete clinicopathological information or treated for a
glandular neoplasm from questionable origin were excluded.
Immunohistochemistry and immunostaining assessment
Immunohistochemical analyses were performed using a standard
protocol extensively described previously.2,18–20 The following
antibodies were used for the primary reaction: anti-keratin (Krt) 7
(clone SP52; Ventana Medical Systems, Tucson, AZ, USA), anti-
Krt16 (clone LL025, Thermo Scientiﬁc, Rockford, IL, USA), anti-Krt20
(clone SP33; Ventana Medical Systems), anti-CDX2 (clone
EPR2764Y; Ventana Medical Systems), anti-p16ink4 (clone JC8;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Ki67 (clone
Mib-1; Dako, Glostrup, Denmark), anti-CD4 (clone SP35; Ventana
Medical Systems), anti-CD8 (clone SP57; Ventana Medical
Systems), anti-PD-1 (clone NAT105; Abcam, Cambridge, MA,
USA), anti-PD-L1 (clone 28-8; Abcam), anti-Foxp3 (clone 236 A/
E7; eBioscience, San Diego, CA, USA) and anti-EGFR (clone 5B7,
Ventana Medical Systems). The mouse/rabbit Envision (Dako) or
Novolink polymer (Leica Biosystems, Wetzlar, Germany) detection
systems were used for the secondary reaction. Mouse and rabbit
control IgGs (Santa Cruz Biotechnology) were utilised as negative
controls.
All immunolabelled tissues were evaluated independently by
experienced histopathologists. Krt7, Krt16, Krt20 and CDX2
immunostainings were scored as positive when a strong/uniform
immunoreactivity was detected in more than 90% of epithelial
cells. The growth fraction (proliferative index) of a given tumour
was determined with the percentage of Ki67-positive cells.
Collected results were stratiﬁed as follows: 0–5%, 6–25%,
26–50%, 51–75%, and > 75%. A similar scoring stratiﬁcation was
used to assess nuclear/cytoplasmic p16ink4 immunoreactivity. T cell
subsets (CD4+, CD8+, Foxp3+ and PD-1+) inﬁltrating the epithelial
component of the tumour or the stroma surrounding cancer cells
were quantiﬁed by computerised counts (QuPath 0.1.2 open
source software for digital pathology image analysis) and veriﬁed
by manual counting. The number of positive cells was reported to
tumour area yielding a count expressed as number of cells/mm2.
As previously described,19,21 both PD-L1 and EGFR immunolabelled
tissues were evaluated by using a semi-quantitative score of the
intensity (0: undetectable, 1: low, 2: moderate, 3: strong) and extent
(0:<5% positive cells, 1: 6–33%, 2: 34–66%, 3: >67%) of the staining,
according to an arbitrary scale. The results obtained with these two
scales were multiplied in order to obtain a global score ranged
between 0 and 9 for each specimen.
HPV genotyping and physical status
The simultaneous detection of 14 carcinogenic (high-risk) HPV
genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68)
was performed using the Abbott RealTime High-Risk HPV assay
(Abbott, Wiesbaden, Germany). As previously demonstrated,22 this
test is highly sensitive for detecting HPV infection in parafﬁn-
embedded tissues.
The HPV16 and 18 physical status (episomal, mixed, integrated)
was determined by analysing the disruption of the HPV E2 gene
expression by quantitative real-time PCR (ABI-Prism 7900 HT
Sequence Detection System, Applied Biosystems, Foster City, CA,
USA). Both thermal cycling conditions and primer sequences are
available in Supplementary materials and methods. Each experi-
ment was performed in triplicate and normalised to the amount of
GAPDH mRNA from the same sample. The E6/E2 ratio cut-off value
was determined, as previously described.23
In situ hybridisation
DNA in situ hybridisation was performed according to the
manufacturer’s instructions. The most common carcinogenic
HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66)
were detected using a probe cocktail (INFORM HPV III Family 16
Probe, Ventana Medical Systems). Red Counterstain II (Ventana
Medical System) was used in order to facilitate microscopic
observation.
Microsatellite instability (MSI) assessment
The MSI status of tumour specimens was determined using the
pentaplex PCR assay described by Buhard et al. and comprising 5
quasimonomorphic mononucleotide repeats (NR-27, NR-21, NR-
24, BAT-25, and BAT-26).24,25 Each collected tissue sample was
carefully reviewed by a histopathologist in order to ascertain that
the percentage of neoplastic cell was higher than 40%. When
cancer cell enrichment was necessary, tumour areas were
macrodissected with a scalpel before tissue digestion. Genomic
DNA extraction, PCR conditions and primer sequences are detailed
in Supplementary materials and methods. PCR products labeled
with ﬂuorescent dyes were analysed with an ABI 3500xL Genetic
Analyzer (Applied Biosystems). As recommended by the revised
Bethesda guidelines,26 tumours displaying differences in the
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length of two or more microsatellite sequences (markers) were
interpreted as being MSI-High. Lesions showing no instability or
one instable repeat were deﬁned as microsatellite stable (MSS)
and MSI-Low, respectively.
Mutation analysis using next-generation sequencing (NGS)
As described above, all analysed samples contained at least 40%
tumour cells. Both tissue lysis and DNA extraction were performed
using QIAamp DNA FFPE Tissue Kit (Qiagen, Valencia, CA, USA)
according to supplier’s recommendations. Frequently mutated
regions of 10 clinically relevant genes in the gastrointestinal
cancer setting [KRAS [exons 2, 3 and 4 (full)], NRAS [exons 2, 3 and
4 (full)], BRAF [exons 11 and 15 (full)], PIK3CA [hotspots in exon 9
and 20 (codons 542, 545 and 1047 covered)], EGFR [exons 18, 19,
20 and 21 (full)], HER2 [exon 22 (full)], KIT [exons 9, 11, 13, 14, 17
and 18 (full)], PTEN [exons 5 and 7 (full)], PDGFRA [exons 12, 14 and
18 (full)], DDR2 [exon 18 (full)]] were ampliﬁed and sequenced
using NGS technology. The detailed protocol is available
in Supplementary materials and methods.
Methylation-speciﬁc PCR (MSP)
DNA isolated from anal tissue specimens were subjected to
bisulﬁte treatment according to the manufacturer’s instructions
(Promega, Madison, WI, USA). Both detailed procedure and primer
sequences targeting p16ink4 promoter were previously
described.27 PCR products were loaded on 2% agarose gels,
stained with ethidium bromide and visualised with an UV
transilluminator (Bio-Rad, Hercules, CA, USA).
Statistical analysis
All collected data were processed using the R (version 3.3.3) or
GraphPad Prism 5 software packages. Differences were considered
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Fig. 1 Identiﬁcation of two distinct subtypes of anal adenocarcinoma. a Schematic representation of the anal canal. b Histology of the
different parts of the anal canal and characterisation of several region-speciﬁc biomarkers (Krt16: squamous zone; Krt7: anal glands/
transitional zone; Krt20 and CDX2: colorectal zone). c Phenotypic analyses reveal two region-speciﬁc subpopulations of primary anal canal
adenocarcinoma. Note the diffuse Krt7 immunoreactivity displayed by tumours arising from the anal glands/transitional zone. In contrast,
colorectal-type anal adenocarcinoma strongly expressed both Krt20 and CDX2 and stained negative for Krt7. The scale bar represents 100 μm
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statistically signiﬁcant when p < 0.05. A two-tailed Student’s t-test
was used to determine the statistical difference between two
groups of immunostained specimens. The comparison of clin-
icopathological data between independent groups was performed
by using Fisher’s exact test or a χ2 test. Disease-free (DFS) and
overall (OS) survivals were deﬁned as the time between the
original diagnosis/biopsy and the date of recurrence (at the
primary or distant site) or death (from any cause), respectively.
When the event did not occur, the date of the last follow-up visit
was used as the endpoint. The Kaplan–Meier methods was used to
estimate both the OS and DFS. For multivariate analysis of
clinicopathological variables related to outcome, a COX regression
model was performed in which signiﬁcant risk factors in univariate
analysis were included (in this particular case, a cutoff at p < 0.10
was used).
RESULTS
Region-speciﬁc proteins reveal two distinct subtypes of primary
adenocarcinoma of the anal canal
The anal canal can be histologically divided into three parts: (1)
the external zone lined by a squamous epithelium, (2) the
transitional zone covered by an “urothelium-like” epithelium and
(3) the colorectal zone. Anal glands, responsible for mucus
secretion, open directly in the transitional zone (Fig. 1a). The
microscopic detection of hair follicles and/or sweat glands
delineates the perianal skin (anal margin) from the squamous
portion of the anal canal. In contrast, similar to the rectum, the
upper centimeter of the anal canal is lined by a colorectal
epithelium preventing a clear demarcation of these two structures
by microscopy. Therefore, medical imaging modalities (endo-
scopic ultrasound, computed tomography scan and/or magnetic
resonance imaging) were used to ascertain the anal origin of all
selected specimens. We previously performed proteomic analysis
of micro-dissected parafﬁn-embedded tissues and discovered
biomarkers that demarcated the different portions of the normal
anal canal.2 As shown in Fig. 1b, Krt16 is speciﬁcally expressed in
the squamous zone, whereas Krt7 is only detected in the anal
transitional zone/anal glands. As for Krt20 and CDX2, their
simultaneous expressions highlight the colorectal epithelium. In
the present study, the robustness of these biomarkers was ﬁrst
assessed with 40 normal anal canal specimens and a 100%
speciﬁcity/sensitivity was observed for all of them. All collected
primary adenocarcinoma of the anal canal were then immunos-
tained and the expression proﬁle of region-speciﬁc proteins clearly
showed two distinct subtypes of glandular neoplasms (Fig. 1c).
Out of 74 cancer specimens, 26 (35.1%) displayed a diffuse Krt7
immunoreactivity and an absence of Krt20/CDX2 expression. The
opposite pattern was observed in “colorectal-type” anal adeno-
carcinoma which were more frequently detected (48/74, 64.9%)
compared to their counterparts arising from the anal glands/
transitional zone. In agreement with the columnar differentiation
displayed by all these tumours, the expression of Krt16 (Fig. 1c)
and other squamous markers such as p63 and Krt14 (data not
shown) was never detected. As illustrated in Supplementary
Figure 2, a minority of tumours originated from the colorectal
zone of the anal canal were negative for Krt20 (4/48, 8.3%) or
displayed a patchy Krt7 immunoreactivity (5/48, 10.4%).
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adenocarcinoma. a Representative examples of primary adenocarcinoma of the anal canal stained for p16ink4. b Semi-quantitative evaluation
of this surrogate biomarker for HPV infection in both anal gland/transitional zone-type and colorectal-type cancers. Note the strong/diffuse
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Almost half of glandular neoplasms arising from the anal glands/
transitional zone are etiologically linked to high-risk HPV infection
Carcinogenic HPV genotypes are detected in most (~95%) anal
squamous (pre)neoplastic lesions. To examine the possible
etiological link between HPV infection and glandular carcinoma
development within the anal canal, we ﬁrst analysed the
expression of p16ink4 (a surrogate biomarker for high-risk HPV
detection) in our cohort of anal adenocarcinoma. Representative
examples are shown in Fig. 2a. A strong and diffuse p16ink4
immunoreactivity (>50% positive cells) was observed in 15
invasive cancers [12 (12/26, 46.2%) anal gland/transitional zone-
type adenocarcinoma and 3 (3/48, 6.3%) malignant lesions arising
from the colorectal zone] (Fig. 2b). The presence of HPV was
conﬁrmed by both in situ hybridisation (Fig. 2c) and PCR (Fig. 2d)
in 11 (11/26, 42.3%) Krt7-positive malignancies. HPV16 and 18
genotypes were identiﬁed in 8 (72.7%) and 3 (27.3%) cases,
respectively. No multiple infection was observed. In contrast, HPV
DNA was not detected in any of the colorectal-type anal
adenocarcinoma. Because of insufﬁcient extracted DNA, the HPV
status was undetermined in 1 patient (1/48, 2.1%) with colorectal-
type anal adenocarcinoma. In order to determine the physical
status of HPV infection, E2 and E6 gene expression was evaluated
by real-time PCR. In view of collected E2/E6 ratios, HPV DNA was
exclusively episomal in 5 cases (5/11, 45.5%), mixed in 5 tissue
samples (5/11, 45.5%) and integrated in 1 specimen (1/11, 9%)
(Fig. 2e). These latter results correlated with the staining patterns
found by in situ hybridisation. Altogether, these ﬁndings were
construed as direct evidence for a transcriptionally active HPV
infection in around half of primary anal adenocarcinomas
originating from the anal glands/transitional zone.
Several clinicopathological characteristics of patients vary
according to the micro-anatomical origin of tumours
Clinicopathological data from 74 patients with histologically
conﬁrmed anal adenocarcinoma and treated between January
1999 and October 2016 were collected from 6 University Hospital
Centers. As mentioned above, based on medical imaging results,
all these glandular tumours were strictly located within the anal
canal. Overall, patients were relatively aged (mean: 67, ranged
from 36 to 94 years) and males slightly outnumbered females
(male/female ratio: 1.24). Approximately half (38/74, 51.4%) of
patients had a lymphatic node involvement and 9 (12.2%) patients
had distant metastasis (mainly in the liver (6/9, 66.7%)) at
presentation. Most patients (42/74, 56.8%) underwent surgery
(abdominoperitoneal resection or local excision) with neoadjuvant
or postoperative chemoradiotherapy. The prescribed radiotherapy
dose was usually 45 Gy (in 25 fractions) and 5-Fluorouracil was the
most commonly used chemotherapeutic drug. A few patients also
received FOLFOX (Folinic acid, 5-Fluorouracil and Oxaliplatin)
Table 1. Demographic and patient characteristics according to
tumour subtype/origin
Characteristics Anal gland/
transitional-type
(n= 26) (35.1%)
Colorectal-
type (n= 48)
(64.9%)
P-value
Age at diagnosis (mean:
67) (range: 36–94) (years)
1
<65 12 (46.2%) 22 (45.8%)
≥65 14 (53.8%) 26 (54.2%)
Gender 1
Male 14 (53.8%) 27 (56.3%)
Female 12 (46.2%) 21 (43.7%)
Inﬂammatory bowel
disease
0.049
Negative 22 (84.6%) 47 (97.9%)
Positive 4 (15.4%) 1 (2.1%)
HIV infection /
Negative 26 (100%) 48 (100%)
Positive 0 (0%) 0 (0%)
HPV infection <0.001
Negative 15 (57.7%) 47 (97.9%)
Positive 11 (42.3%) 0 (0%)
Undetermined 0 (0%) 1 (2.1%)
HPV genotypes /
HPV16 8 (72.7%) 0 (0%)
HPV18 3 (27.3%) 0 (0%)
Others 0 (0%) 0 (0%)
Proliferative index (Ki67) 0.003
≤25% 7 (26.9%) 4 (8.3%)
26–50% 11 (42.3%) 10 (20.9%)
51–75% 7 (26.9%) 17 (35.4%)
>75% 1 (3.9%) 17 (35.4%)
Tumour differentiation 0.313
Well-differentiated 9 (34.6%) 25 (52.2%)
Moderately
differentiated
13 (50%) 16 (33.3%)
Poorly differentiated 4 (15.4%) 7 (14.5%)
cTNM
cT 0.339
T1–T2 14 (53.8%) 20 (41.7%)
T3–T4 12 (46.2%) 28 (58.3%)
cN 1
N− 13 (50%) 23 (47.9%)
N+ 13 (50%) 25 (52.1%)
cM 0.479
M− 24 (92.3%) 41 (85.4%)
M+ 2 (7.7%) 7 (14.6%)
Tumour stage (UICC) 0.847
Stage I 2 (7.7%) 3 (6.3%)
Stage II 11 (42.3%) 20 (41.7%)
Stage III 11 (42.3%) 18 (37.5%)
Stage IV 2 (7.7%) 7 (14.5%)
Primary treatment 0.062
(neo)adjuvant
chemoradiotherapy/
surgery
11 (42.3%) 31 (64.6%)
Table 1 continued
Characteristics Anal gland/
transitional-type
(n= 26) (35.1%)
Colorectal-
type (n= 48)
(64.9%)
P-value
(neo)adjuvant
radiotherapy/surgery
4 (15.4%) 1 (2.1%)
(neo)adjuvant
chemotherapy/surgery
1 (3.9%) 1 (2.1%)
Chemoradiotherapy 2 (7.7%) 0 (%)
Radiotherapy 3 (11.5%) 3 (6.3%)
Chemotherapy 2 (7.7%) 1 (2.1%)
Surgery 3 (11.5%) 7 (14.5%)
No treatment 0 (0%) 4 (8.3%)
Bold values indicate statistically signiﬁcant differences
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(9/74, 12.2%) (mainly as adjuvant treatment) or Capecitabine
(Xeloda) (4/74, 5.4%). As listed in Table 1, when tumour origin
(determined by the Krt7/20-CDX2 expression proﬁle) was taken
into account for subclassifying patients into two groups, no
signiﬁcant difference was noted with respect of age at diagnosis
(p= 1), gender (p= 1), tumour differentiation (p= 0.313), TNM
classiﬁcation (T, p= 0.339; N, p= 1; M, p= 0.479), tumour stage (p
= 0.847) and treatment (p= 0.062). No patient was HIV positive.
As mentioned earlier, high-risk HPV infection (HPV16 or HPV18)
was only detected in neoplastic lesions arising from the anal
glands/transitional zone (p < 0.001). Signiﬁcantly, these latter
tumours displayed a lower proliferative index compared to their
counterparts originating from the colorectal mucosa (p= 0.003).
Crohn’s disease and ulcerative colitis were also statistically
correlated with tumour origin (p= 0.049). With the exception of
one case (1/48, 2.1%), all these inﬂammatory conditions were
observed in patients with anal gland/transitional zone-type
tumours (4/26, 15.4%). Three out of 4 (75%) were associated with
chronic perianal ﬁstulas. Finally, patients’ characteristics for Krt7-
positive anal adenocarcinoma according to HPV status are shown
in Supplementary Table 1. Although HPV-positive tumours tended
to be diagnosed in younger patients compared to uninfected
cancers, similarly to all other clinicopathological variables,
statistical signiﬁcance was not reached. These results might be
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Time (months)
Disease-free survival
HR (95% Cl) univariate analysis HR (95% Cl) univariate analysis
Age at diagnosis
(<65 vs >65)
Age at diagnosis
(<65 vs >65)
Gender
(men vs women)
IBD
(yes vs no)
HPV infection
(yes vs no)
Proliferation index
(<50% vs >50%)
Tumour differentiation
(well vs moderate/poor)
cT
(T1-T2 vs T3-T4)
cT
(T1-T2 vs T3-T4)
cN
(N– vs N+)
HR (95% Cl) HR (95% Cl)
cN
(N– vs N+)
cN
(N– vs N+)
Radiotherapy
(yes vs no)
Chemotherapy
(yes vs no)
Tumour origin
(anal glands vs colorectal)
1.01 (0.42 – 2.37) 2.64 (1.12 – 6.21)
1.42 (0.61 – 3.29)
1.06 (0.22 – 4.05)
1.69 (0.66 – 4.32)
0.73 (0.31 – 1.69)
2.01 (0.74 – 5.41)
1.67 (0.73 – 3.84)
2.21 (0.94 – 5.20)
1.28 (0.43 – 3.77)
1.32 (0.54 – 3.24)
1.89 (0.83 – 4.33)
p= 0.997 p= 0.021
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related to the weak number of patients in each category (lack of
statistical power).
Patients treated for anal gland/transitional-type or colorectal-type
anal adenocarcinoma undergo frequent recurrences and are
associated with a similar likelihood of adverse outcome
Out of 74 patients diagnosed with adenocarcinoma strictly located
in the anal canal, 65 (87.8%) were incorporated in both OS and
DFS analysis. Nine (12.2%) patients were excluded because of
distant metastasis at the time of diagnosis (UICC stage IV).
Furthermore, 5 (55.6%) of these latter metastatic patients did not
receive any treatment. Median follow-up was 33.1 months (range:
2–141 months). After treatment completion, local or distant
recurrence occurred in 10 (10/24, 41.7%) patients with invasive
neoplasms originating from the anal glands/transitional zone and
in 13 (13/41, 31.7%) patients with colorectal-type anal adenocar-
cinoma. The two tumour subtypes displayed similar patterns of
local/metastatic recurrences and, whatever the tumour origin, all
distant recurrences were found either in the liver or the lung.
Among the patients who died during the follow-up period, 11 (11/
24, 45.8%) and 13 (13/41, 31.7%) exhibited a neoplastic lesion who
developed from the anal glands/transitional zone or from the
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colorectal mucosa anatomically located in the anal canal,
respectively. Cancer was the cause of the death in three quarter
of cases (18/24, 75%). As illustrated by the Kaplan-Meier survival
curves (Fig. 3a, b), patients with primary anal adenocarcinoma
frequently experienced a poor outcome. In particular, patients
treated for anal gland/transitional-type cancer tended to have
shorter 5-years DFS (33.1% versus 52.6%) and OS (27.8% versus
50.4%) compared with those with a colorectal-type neoplasm.
Statistical signiﬁcance was not reached (Fig. 3c–f).
Age at diagnosis, nodal status and tumour size signiﬁcantly impact
the outcome of patients treated for anal adenocarcinoma
In order to better predict the outcome of patients, the prognostic
values of each clinicopathological variable (risk factor) associated
with DFS and OS were then determined. Forest plots for both
univariate and multivariate analysis are shown in Fig. 3c–f. Both
DFS and OS did not signiﬁcantly differ with patient gender,
concomitant inﬂammatory condition, HPV status, proliferative
index, tumour differentiation, chemotherapy use and radiotherapy
(Fig. 3c–d). In univariate analysis, N-stage positivity was signiﬁ-
cantly related to reduced DFS (p= 0.017) (a tendency was also
observed with OS (p= 0.064)) whereas tumour size (p= 0.031)
and age at diagnosis (p= 0.021) were independently associated
with reduced DFS and OS, respectively. The prognostic value of
patient age (p= 0.017) and N-stage (p= 0.044) for OS was further
conﬁrmed by multivariate analysis (Fig. 3e–f). When all the
parameters (irrespective of the signiﬁcance in univariate analysis)
were included in multivariate analysis, no other signiﬁcant risk
factor was revealed.
Region-speciﬁc subtypes of anal adenocarcinoma display different
mutational patterns for downstream effectors of the EGFR
signalling pathway
As described above, both subtypes of anal adenocarcinoma are
globally associated with an unfavorable outcome. In order to offer
treatment alternatives that might improve the poor existing 5-year
survival rate and reduce the frequency of local/distal recurrences
(Fig. 3), it is essential to have a precise characterisation of the
disease (expression of targetable proteins, genetic underpinnings,
immune microenvironment,…). We ﬁrst investigated EGFR expres-
sion by immunohistochemistry in both subtypes of anal columnar
lesions identiﬁed in the present study. Representative examples of
EGFR immunolabelled tissues are shown in Fig. 4a. Overall, EGFR
expression was detected in the large majority of cancers (64/74,
86.5%). With the exception of one case, all stage III and IV tumours
were positive (37/38, 97.4%). When both the intensity and the
extent of the staining were taken into account, EGFR expression
was signiﬁcantly higher in colorectal-type adenocarcinoma
compared to anal gland/transitional-type neoplasms (Fig. 4b). In
the last decade, signiﬁcant improvement in the treatment of
several cancers (i.e., metastatic colorectal cancer, non-small cell
lung cancer or head and neck SCC) has been obtained with the
use of monoclonal anti-EGFR antibodies. However, somatic
mutations in one or several downstream effector(s) of the EGFR
signalling pathway were clearly shown to be associated to
resistance to anti-EGFR drugs (cetuximab and panitumumab).28,29
Therefore, the prevalence rates of KRAS, NRAS, BRAF, PIK3CA, EGFR,
HER2 and PTEN mutations were determined in all collected anal
adenocarcinoma specimens. The mutational status of three other
clinically relevant genes in the gastrointestinal cancer setting (KIT,
PDGFRA and DDR2) was also assessed. Because of poor DNA
quality (high degradation), 6 samples out of 74 (8.1%) were
excluded. As revealed by NGS analysis (Fig. 4d–f), a high
percentage (47.1%) of anal adenocarcinoma harbored a KRAS
mutation. In contrast, mutations in other genes were relatively rare
(NRAS (5.9%), BRAF (1.5%), PIK3CA (7.6%), PTEN (2.9%)) or
completely absent (EGFR, HER2, KIT, PDGFRA and DDR2). No case
had concurrent KRAS and NRAS mutations (Fig. 4d). Interestingly,
when both tumour origin and HPV status were taken into account,
the rate of KRAS mutations was signiﬁcantly lower in anal gland/
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transitional-type neoplasms (8/24, 33.3%) (especially in HPV-
positive tumours (2/10, 20%)) compared to their colorectal-type
counterparts (24/44, 54.5%) (Fig. 4d, e). Finally, MSI was assessed
and differences in the length of two or more mononucleotide
repeats (indicative of MSI-high status) were only observed in one
(1/74, 1.4%) anal adenocarcinoma (Fig. 4c and Supplementary
Figure 3).
The stroma surrounding anal gland/transitional-type anal
adenocarcinoma is characterised by a prominent T-cell inﬁltration
Immunotherapy represents a great hope for many patients
currently facing diseases associated with unfavorable outcomes
and poor response rates to “classical” chemoradiotherapy.
However, the therapeutic efﬁcacy of drugs targeting the PD-1/
PD-L1 axis (immune checkpoint inhibitors) relies on a high
preexisting T-cell inﬁltration within tumour microenvironment. In
order to determine whether anal glandular neoplasms meet this
criteria, PD-L1 expression in epithelial (tumour) cells as well as
intratumoural CD4+, CD8+, Foxp3+, and PD-1+ T cell densities
were analysed by immunohistochemistry (Fig. 5a). These latter
immune cell subsets were quantiﬁed by computerised counting
(Supplementary Figure 4). Strikingly, higher T-cell inﬁltrates were
observed in anal gland/transitional-type anal adenocarcinoma
compared to tumours arising from the colorectal mucosa (Fig. 5c).
Whatever the immune cell subpopulations, the large majority of
positive cells (>90%) were detected in the stroma surrounding
cancer cells. Within anal gland/transitional-type tumours, HPV-
positive neoplasms were frequently associated with a highly
inﬂammatory tumour microenvironment (Fig. 5c). Beside T-cell
subsets, epithelial PD-L1 expression was also statistically more
important in anal adenocarcinomas arising from the anal glands/
transitional zone compared to their Krt20/CDX2-positive counter-
parts (Fig. 5b).
DISCUSSION
Anal adenocarcinoma remains a challenge for gastroenterologists,
abdominal surgeons and oncologists because of its low incidence,
unclear pathogenesis and high recurrence rate. So far, no
epidemiologic, genetic and immunologic data are available and
only a few studies (mainly case reports) focused on this rare and
aggressive disease. Altogether, our ﬁndings indicate that the
cellular origin (anal glands/transitional zone versus colorectal
mucosa anatomically located under the anorectal ﬂexure) of anal
glandular neoplasms inﬂuences their natural history, mutational
proﬁle and immune microenvironment. Although the tumours
were morphologically similar, keratin/CDX2 expression was ﬁrst
shown to be highly speciﬁc and sensitive for distinguishing the
two adenocarcinoma subtypes described in the present article.
The shared expression pattern detected in both normal tissues
and invasive cancers further conﬁrms the increasing use of keratin
ﬁlaments as reliable biomarkers for correlating tumour origin with
patient management.30 Moreover, the restricted expression of Krt7
in tumours arising from the anal glands/transitional zone is
consistent with prior case reports31–33 and parallels the staining
pattern of this biomarker in anal SCC located at the squamoco-
lumnar junction.2,3
The carcinogenic potential of some HPV genotypes (most
notably HPV16 and 18) was ﬁrst reported in early 80s.34 Every year,
about 630,000 SCC attributable to HPV infection are diagnosed
worldwide.35 These latter are mainly diagnosed in the uterine
cervix but increasing incidences are currently observed in both
anal canal and oropharynx. Frequently under-estimated by both
virologists and epidemiologists, carcinogenic HPV genotypes are
also involved in the development of the majority (~75–80%) of
cervical adenocarcinoma.36 Interestingly, transcriptionally active
HPV infections were recently found in Barrett’s adenocarcinoma,37
another glandular neoplasm developing within a
squamocolumnar junction. To the best of our knowledge, this
report provides the ﬁrst evidence of a causal link between HPV
infection and anal adenocarcinoma. Similarly to other HPV-
positive adenocarcinoma diagnosed in the uterine cervix or
oesophagus, only anal glandular neoplasms (11/26, 42.3%) arising
from the transitional zone were infected by HPV16 or 18. Although
several possible mechanisms were recently highlighted,38 the high
susceptibility of junctional/transitional tissues to HPV infection is
still the subject of active investigations. Despite a few false-
positive (p16ink4 positive/HPV negative) results (4/63, 6.3%) that
were also shown in the context of both anal and oropharyngeal
SCC,2,6,39 the reported correlation between high-risk HPV infection
and diffuse p16ink4 immunoreactivity was expected. The surprising
result was that ﬁve (5/11, 45.5%) HPV-infected tumours displayed
some patches (representing up to one third of the whole tumour
area) of p16ink4 negativity. Given that aberrant methylation of
p16ink4 promoter is frequently observed in adenocarcinoma
arising from the gastrointestinal tract,40,41 MSP experiments were
performed and CDKN2A (p16ink4) promoter hypermethylation was
detected in 4 out of 5 tumour samples (Supplementary Figure 5).
During the last 20 years, local excision, combined chemor-
adiotherapy and radical surgery with or without (neo)adjuvant
chemotherapy have been successively proposed as the gold
standard treatment for these aggressive anal glandular tumours.16
Unfortunately, conﬂicting results exist due to the low number of
followed patients in most studies.16 To date, only one study
conducted by the Rare Cancer Network analysed more than 50
patients and observed better survival rates after combined
chemoradiotherapy compared to radiotherapy/surgery. However,
patients treated with this latter combination were signiﬁcantly
older, making difﬁcult the comparison between the two groups.9
Accordingly, our ﬁndings demonstrated that patient age was an
independent predictor for decreased OS. Therefore, with the
exception of local surgery for stage I tumour, as reported in the
present study and suggested by the discrepancies in the literature,
no standard treatment was shown to clearly improve patient
outcome.
First suggested by Paul Ehrlich one century ago, the concept of
targeted therapy has gained momentum since early 2000s with the
clinical success of inhibitors such as trastuzumab (for both breast
and gastric cancers) or imatinib (for chronic myeloid leukaemia).42
Treatment algorithms of numerous cancers have changed
dramatically over the last few years due to the advent of novel
targeted drugs. In the context of cancers diagnosed within the
gastrointestinal tract, two anti-EGFR monoclonal antibodies
(cetuximab and panitumumab) in combination with FOLFIRI were
recently approved for the ﬁrst-line treatment of metastatic
colorectal cancers.43,44 However, their efﬁcacy strongly depends
on both EGFR expression and mutational status of its downstream
effectors (KRAS, NRAS, BRAF, PI3KCA, PTEN).28,29 While EGFR
expression was detected in the large majority (64/74, 86.5%) of
both subtypes of anal adenocarcinoma irrespective of the HPV
status, interestingly, the frequencies of KRAS/NRAS mutations were
signiﬁcantly higher in HPV-negative tumours compared to their
infected counterparts. The low rates of both KRAS and NRAS
mutations reported in neoplastic lesions etiologically linked to HPV
concurred with the recent results documented for cervical
adenocarcinoma.45 Regarding the low prevalence of both BRAF
mutations and MSI-high specimens observed in the present study,
these latter results are in agreement with those of Yamauchi et al.46
who showed a gradual decrease of these two parameters along
the gastrointestinal tract from the ascending colon to the rectum.
Chosen by Science’s editors as the breakthrough of the year for
2013,47 cancer immunotherapy using immune checkpoint inhibi-
tors (especially drugs targeting the PD-1/PD-L1 axis) has raised
much interest for cancer treatment over the last few years.
However, their efﬁcacy for reactivating lymphocyte-mediated
cytotoxicity relies on a high pre-existing T cell inﬁltration of the
A dualistic model of primary anal canal adenocarcinoma
M. Herfs et al.
1310
tumour microenvironment. Importantly, we reported here that T
cell densities (CD4, CD8, Foxp3 and PD-1) detected in the tumour
stroma surrounding cancer cells (especially HPV-positive ones)
originating from the anal glands/transitional zone were signiﬁ-
cantly higher than those found in the vast majority of colorectal-
type tumours. Moreover, a similar signiﬁcant increase was also
observed for the expression of PD-L1 by tumour cells. Not related
to the MSI status of tumours, these data are likely to be explained
by the chronic inﬂammation frequently observed in squamoco-
lumnar junctions48 and/or by the detection of transcriptionally
active HPV infection in approximately half (42.3%) of anal gland/
transitional-type adenocarcinoma. Indeed, several recent studies
described a signiﬁcant increased density of both effector (CD4/
CD8) and regulatory (Foxp3) tumour inﬁltrating T lymphocytes in
HPV-positive compared to HPV-negative SCC and highlighted the
predictive value of CD4/CD8 inﬁltrates.49 These latter results and
those reported in the present article are supportive of the dozen
ongoing clinical trials evaluating immune-checkpoint inhibitors in
the setting of HPV-positive cancers.
Taken together, our ﬁndings highlight the existence of two
subtypes of anal adenocarcinoma with distinct cells of origin.
Whatever the tumour subtypes, metastatic patients with wild-type
downstream effectors of the EGFR signalling pathway could
reasonably be expected to beneﬁt from anti-EGFR monoclonal
antibodies. Displaying a strong Krt7 immunoreactivity, tumours
arising from the anal glands/transitional zone were shown to be
associated with prominent T cell inﬁltrates and high expressions of
PD-1/PD-L1 suggesting that immune checkpoint inhibitors could
also represent promising alternatives to current sub-optimal
treatment algorithms. Although further studies are still needed,
determining the cellular origin of these rare tumours with the
speciﬁc/sensitive biomarkers validated in the present study could
therefore be helpful for clinicians currently struggling with this
aggressive neoplastic condition.
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